AACR-NCI-EORTC International Conference:
Molecular Targets and Cancer Therapeutics
November 12-16, 2011
Moscone Center West
San Francisco, CA
The 2011 Molecular Targets and Cancer Therapeutics Conference is not accredited for Continuing Medical Education Credit. Questions about CME can be directed to the AACR Office of CME at cme@aacr.org or call 215-440-9300.
SCIENTIFIC COMMITTEE CO-CHAIRPERSONS:
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA, USA (AACR)
James H. Doroshow, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA (NCI)
Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands (EORTC)
The 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications will take place November 12-16, 2011 at the Moscone Center West in San Francisco, California. This major conference brings together over 3,000 academics, scientists, and representatives from the pharmaceutical industry to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology. During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomized, multicenter cancer clinical trials. Together, the level of excitement surrounding targeted therapy and the high caliber of the science presented fuel the power of this meeting to attract the world’s leaders in the development of new cancer therapeutics.
ORGANIZING COMMITTEE CO-CHAIRPERSONS:
Elizabeth H. Blackburn, University of California, San Francisco, CA, USA (AACR)
Douglas R. Lowy, National Cancer Institute, Bethesda, MD, USA (NCI)
Jean-Yves Blay, Centre Léon Berard, Lyon, France (EORTC)
SCIENTIFIC COMMITTEE:
Ahmad H. Awada, Institut Jules Bordet, Brussels, Belgium
José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Jean-Yves Blay, Centre Léon Bérard, INSERM U-453, Lyon, France
Helen X. Chen, National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA
Jerry M. Collins, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
Barbara A. Conley, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
Johann S. de Bono, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK
E.G. Elisabeth De Vries, University Medical Center Groningen, Groningen, The Netherlands
Christian Dittrich, Ludwig Boltzmann-Institute for Applied Cancer Research, Vienna, Austria
Hans Gelderblom, Leiden University Medical Center, Leiden, The Netherlands
Giuseppe Giaccone, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA
Jennifer Rubin Grandis, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Louise Barnett Grochow, AstraZeneca, Waltham, MA, USA
William N. Hait, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA
Nadia Harbeck, University Hospital of Cologne, Cologne, Germany
Ernest T. Hawk, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Toby Hecht, National Cancer Institute, Translational Research Program, Rockville, MD, USA
Lee J. Helman, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA
Roy S. Herbst, Yale Cancer Center, New Haven, CT, USA
Sandra J. Horning, Genentech, South San Francisco, CA, USA
S. Percy Ivy, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Rockville, MD, USA
Denis A. Lacombe, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
Lawrence J. Marnett, Vanderbilt University Medical Center, Nashville, TN, USA
David R. Newell, Northern Institute for Cancer Research, Newcastle Upon Tyne, UK
Wim J.G. Oyen, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
Ralph E. Parchment, National Cancer Institute, Science Applications International Corporation, Frederick, MD, USA
David R. Parkinson, Nodality, South San Francisco, CA, USA
Yves G. Pommier, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA
Robert Radinsky, Amgen, Thousand Oaks, CA, USA
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Patrick Schöffski, University of Leuven, Leuven Cancer Institute, Leuven, Belgium
Lillian L. Siu, University of Toronto, University Health Network, Toronto, ON, Canada
Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France
Patricia S. Steeg, National Cancer Institute, Center for Cancer Research, Bethesda, MD, USA
Josep Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain
Beverly A. Teicher, National Cancer Institute, Developmental Therapeutics Program, Rockville, MD, USA
Joseph E. Tomaszewski, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ, USA
Barbara L. Weber, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
John J. Wright, National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA
Nadia Zaffaroni, Istituto Nazionale Dei Tumori, Milan, Italy
James A. Zwiebel, National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA
The American Association for Cancer Research (AACR), is a nonprofit scientific society that includes 33,000 laboratory, translational and clinical cancer researchers whose mission is to prevent and cure cancer through research, education, communication and collaboration.
The National Cancer Institute (NCI), founded in 1937, is the principal government agency in the United States charged with coordinating the national effort against cancer. It facilitates international cooperation in clinical trials involving U.S. and foreign collaborating institutions.
The European Organization for Research and Treatment of Cancer (EORTC), founded in 1962, conducts, develops, coordinates, and stimulates clinical and translational research in Europe to improve the management of cancer and related problems by increasing survival and quality of life for patients with cancer.